Globus Medical (NYSE: GMED), a leading musculoskeletal solutions company, and Nevro Corp. (NYSE: NVRO), a global medical ...

One of my employees, “Pam,” has been having pains that I won’t specify for the sake of anonymity. Her condition is ...

The U.S. Food and Drug Administration has approved a novel prescription pain medication that targets sodium channels involved ...

Medically reviewed by Amy Kwan, PT Your latissimus dorsi (your "lats") is a broad, flat, triangle-shaped muscle that spans ...

Introducing Journavx: the FDA-approved non-opioid, non-addictive drug for acute pain. A major breakthrough in pain medication ...

Medicare needs to cover non-opioid treatments instead of riskier ones. A new legislative proposal can help cover the cost.

Despite an increase in the use of medication for opioid use disorder in older adults from 2017 to 2022, disparities persist; ...

The new drug is intended for treatment of moderate to severe acute pain in adults. Patients with acute pain after surgery or due to a broken bone or an injury are often prescribed opioid ...

Dr. Sanjay Gupta said Tuesday that the approval of a new non-opioid pain medication is “a pretty big deal.” “This is a pretty big deal,” Gupta said. “As you just mentioned, it’s been ...

CenExel, a leading network of clinical research sites, proudly congratulates and announces its role in supporting Vertex Pharmaceuticals’ clinical studies that led to the FDA approval of JOURNAVX™ ...

When THC attaches to the receptor, the effect is like an off switch to a light bulb, effectively turning "off" the pain. But ...

The use of Journavx for moderate to severe pain has not been studied beyond 14 days. The Food and Drug Administration (FDA) has approved Journavx™ (suzetrigine) for the treatment of moderate to ...